ES2183977T3 - Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado. - Google Patents

Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.

Info

Publication number
ES2183977T3
ES2183977T3 ES96935971T ES96935971T ES2183977T3 ES 2183977 T3 ES2183977 T3 ES 2183977T3 ES 96935971 T ES96935971 T ES 96935971T ES 96935971 T ES96935971 T ES 96935971T ES 2183977 T3 ES2183977 T3 ES 2183977T3
Authority
ES
Spain
Prior art keywords
temozolomide
combination
interferon
alfa
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96935971T
Other languages
English (en)
Inventor
Margaret H Dugan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2183977T3 publication Critical patent/ES2183977T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UN METODO PARA EL TRATAMIENTO DEL CANCER AVANZADO EN PACIENTES QUE LO PRECISEN. LA TEMOZOLOMIDA Y EL INTERFERON ALFA SE ADMINISTRAN COMBINADOS EN CANTIDADES SUFICIENTES PARA OBTENER UNA RESPUESTA CLINICA.
ES96935971T 1995-10-04 1996-10-01 Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado. Expired - Lifetime ES2183977T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US623395P 1995-10-04 1995-10-04
US62541096A 1996-03-27 1996-03-27

Publications (1)

Publication Number Publication Date
ES2183977T3 true ES2183977T3 (es) 2003-04-01

Family

ID=26675350

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96935971T Expired - Lifetime ES2183977T3 (es) 1995-10-04 1996-10-01 Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.

Country Status (10)

Country Link
EP (1) EP0859630B1 (es)
JP (2) JP4156028B2 (es)
AT (1) ATE229343T1 (es)
AU (1) AU719074B2 (es)
CA (1) CA2233544A1 (es)
DE (1) DE69625373T2 (es)
DK (1) DK0859630T3 (es)
ES (1) ES2183977T3 (es)
PT (1) PT859630E (es)
WO (1) WO1997012630A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345240A (zh) * 1999-03-30 2002-04-17 先灵公司 用替莫唑胺改善癌症治疗
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1251866A1 (en) * 2000-01-24 2002-10-30 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
AU2006263331B2 (en) 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
EP0372809B1 (en) * 1988-12-01 1993-08-04 Schering Corporation Medicament for the treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
AU651998B2 (en) * 1990-10-12 1994-08-11 F. Hoffmann-La Roche Ag Use of a retinoid
DE4244548C2 (de) * 1992-12-30 1997-10-02 Stockhausen Chem Fab Gmbh Pulverförmige, unter Belastung wäßrige Flüssigkeiten sowie Blut absorbierende Polymere, Verfahren zu ihrer Herstellung und ihre Verwendung in textilen Konstruktionen für die Körperhygiene

Also Published As

Publication number Publication date
AU7373196A (en) 1997-04-28
AU719074B2 (en) 2000-05-04
EP0859630A1 (en) 1998-08-26
JP2007169300A (ja) 2007-07-05
ATE229343T1 (de) 2002-12-15
DK0859630T3 (da) 2003-03-24
WO1997012630A1 (en) 1997-04-10
DE69625373D1 (de) 2003-01-23
EP0859630B1 (en) 2002-12-11
JP4156028B2 (ja) 2008-09-24
JPH11514995A (ja) 1999-12-21
DE69625373T2 (de) 2003-05-15
CA2233544A1 (en) 1997-04-10
PT859630E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
GEP20002146B (en) Therapeutic Peptide Derivatives
EP0921819A4 (en) CANCER TREATMENT AND PREVENTION THROUGH DERIVATIVES OF HUMAN CHORIO-GONADOTROPINE
DK0880350T3 (da) Behandling af dissemineret sklerose
KR950701350A (ko) 부작용 감소와 동시에 인터페론을 이용한 질환의 치료방법 및 조성물(methods and compositions for the treatment of diseases with interferon while reducing side effects)
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ATE227124T1 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
ES2183977T3 (es) Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
DK0858341T3 (da) Kombinationsbehandling af fremskreden cancer omfattende temozolomid og cisplatin
KR950700737A (ko) 기도 염증 및 기도 과잉반응의 치료약품(Medicament for the treatment of airways inflammation and airways hyperresponsiveness)
UA10928C2 (uk) Спосіб профілактики гіперхолестериhемії
MX9603833A (es) Tratamiento mejorado del cancer con temozolomida.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DK1150981T3 (da) Terapeutisk necleosidforbindelse
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
MX9708885A (es) Uso de ribavirin e interferon alfa para el tratamiento de hepatitis c.
UA23985A (uk) Спосіб лікуваhhя запальhих захворюваhь вhутрішhіх геhіталій у дівчат та підлітків
DE59506911D1 (de) Verwendung von intravenös applizierbarem eisen zur therapie von tumorerkrankungen und/oder infektionskrankheiten